TARS – tarsus pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Form 4 Tarsus Pharmaceuticals, For: Dec 15 Filed by: Goodrich Katherine
Form 8-K Tarsus Pharmaceuticals, For: Jan 12
Form 4 Tarsus Pharmaceuticals, For: Jan 02 Filed by: Whitfield Dianne C.
Form 144 Tarsus Pharmaceuticals, Filed by: Whitfield Dianne C.
Form 4 Tarsus Pharmaceuticals, For: Dec 24 Filed by: Azamian Bobak R.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.